Anna Polli

9.2k total citations · 5 hit papers
80 papers, 4.1k citations indexed

About

Anna Polli is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Anna Polli has authored 80 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 55 papers in Pulmonary and Respiratory Medicine and 16 papers in Genetics. Recurrent topics in Anna Polli's work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (27 papers) and Colorectal Cancer Treatments and Studies (22 papers). Anna Polli is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (27 papers) and Colorectal Cancer Treatments and Studies (22 papers). Anna Polli collaborates with scholars based in Italy, United States and France. Anna Polli's co-authors include Alice T. Shaw, Benjamin Solomon, G. Piscitelli, Tony Mok, Jonathan Webster, Carlo Ferrari, Ikram Shah Ismail, M. F. Scanlon, Dong‐Wan Kim and Giorgio Massimini and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Anna Polli

72 papers receiving 4.0k citations

Hit Papers

First-Line Lor... 1994 2026 2004 2015 2020 1994 2015 2022 2024 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
    2020 649 citations Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine profile →
  2. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
    1994 471 citations G. Piscitelli, Anna Polli et al. New England Journal of Medicine profile →
  3. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases
    2015 468 citations Alice T. Shaw, Sai‐Hong Ignatius Ou et al. Journal of Clinical Oncology profile →
  4. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
    2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
  5. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
    2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Polli Italy 25 2.5k 2.3k 1.0k 943 831 80 4.1k
M. Tubiana-Hulin France 30 3.3k 1.3× 875 0.4× 734 0.7× 1.7k 1.8× 921 1.1× 60 4.6k
Rosalba Torrisi Italy 35 2.4k 1.0× 671 0.3× 724 0.7× 1.9k 2.0× 1.0k 1.2× 130 4.2k
D. Amoroso Italy 23 2.0k 0.8× 791 0.3× 668 0.7× 925 1.0× 455 0.5× 104 2.8k
Joshi J. Alumkal United States 31 1.7k 0.7× 2.8k 1.3× 342 0.3× 1.3k 1.3× 1.8k 2.1× 136 4.7k
Giorgio Massimini Italy 16 1.3k 0.5× 861 0.4× 884 0.9× 705 0.7× 899 1.1× 33 2.8k
Sofia Paul United States 11 1.8k 0.7× 1.9k 0.8× 386 0.4× 244 0.3× 464 0.6× 24 2.7k
Jean‐Marc Nabholtz France 24 1.9k 0.7× 772 0.3× 1.2k 1.2× 1.3k 1.4× 508 0.6× 54 3.2k
Simon Chowdhury United Kingdom 29 1.4k 0.5× 4.0k 1.8× 308 0.3× 1.4k 1.5× 1.0k 1.2× 199 5.1k
J Cuzick United Kingdom 7 2.0k 0.8× 561 0.2× 1.6k 1.6× 2.0k 2.1× 565 0.7× 10 3.6k
Michael J. Demeure United States 36 1.5k 0.6× 823 0.4× 334 0.3× 1.3k 1.4× 1.1k 1.3× 142 4.3k

Countries citing papers authored by Anna Polli

Since Specialization
Citations

This map shows the geographic impact of Anna Polli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Polli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Polli more than expected).

Fields of papers citing papers by Anna Polli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Polli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Polli. The network helps show where Anna Polli may publish in the future.

Co-authorship network of co-authors of Anna Polli

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Polli. A scholar is included among the top collaborators of Anna Polli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Polli. Anna Polli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study. Journal of Clinical Oncology. 42(29). 3400–3409. 118 indexed citations breakdown →
2.
3.
Solomon, Benjamin, Geoffrey Liu, Enriqueta Felip, et al.. (2024). Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer. Future Oncology. 20(40). 3377–3387.
4.
5.
Haydon, Andrew, Dirk Schadendorf, Reinhard Dummer, et al.. (2023). 602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Annals of Oncology. 34. S1707–S1708. 2 indexed citations
6.
Soo, Ross A., Jean‐François Martini, Anthonie J. van der Wekken, et al.. (2023). Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC. Journal of Thoracic Oncology. 18(11). 1568–1580. 22 indexed citations
7.
8.
Schadendorf, Dirk, Reinhard Dummer, Caroline Robert, et al.. (2022). STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma. Future Oncology. 18(17). 2041–2051. 12 indexed citations
9.
Bearz, Alessandra, Enriqueta Felip, Julien Mazières, et al.. (2022). 979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study. Annals of Oncology. 33. S998–S999. 5 indexed citations
10.
Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2022). Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.. Journal of Clinical Oncology. 40(16_suppl). 9070–9070. 4 indexed citations
11.
Solomon, Benjamin, Todd M. Bauer, Sai‐Hong Ignatius Ou, et al.. (2022). Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of Clinical Oncology. 40(31). 3593–3602. 81 indexed citations
12.
Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2021). Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations. Cancer Research. 81(13_Supplement). LB043–LB043. 2 indexed citations
13.
Mazières, Julien, Laura Iadeluca, Alice T. Shaw, et al.. (2021). MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC. Journal of Thoracic Oncology. 16(3). S175–S176. 2 indexed citations
14.
Shaw, Alice T., Todd M. Bauer, Filippo de Marinis, et al.. (2020). First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer. New England Journal of Medicine. 383(21). 2018–2029. 649 indexed citations breakdown →
15.
Soria, Jean‐Charles, Steffan N. Ho, Marileila Varella‐Garcia, et al.. (2018). Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer. Annals of Oncology. 29(9). 1964–1971. 12 indexed citations
16.
Patel, Sandip Pravin, Nathan A. Pennell, Suchita Pakkala, et al.. (2016). Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi449–vi449. 2 indexed citations
17.
Shaw, Alice T., Pasi A. Jänne, Benjamin Besse, et al.. (2016). Crizotinib vs chemotherapy in ALK+ advanced non-small cell lung cancer (NSCLC): Final survival results from PROFILE 1007.. Journal of Clinical Oncology. 34(15_suppl). 9066–9066. 9 indexed citations
18.
Kim, D., Myung‐Ju Ahn, Pan‐Chyr Yang, et al.. (2012). Updated Results of a Global Phase II Study with Crizotinib in Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix402–ix402. 57 indexed citations
19.
Lønning, Per Eystein, Emilio Bajetta, Robin Murray, et al.. (2000). Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. Journal of Clinical Oncology. 18(11). 2234–2244. 242 indexed citations
20.
Kaufmann, M., Emilio Bajetta, Luis Fein, et al.. (2000). Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. European Journal of Cancer. 36. 86–87. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. Tubiana-Hulin Breakdown of academic impact, for papers by Rosalba Torrisi Breakdown of academic impact, for papers by D. Amoroso Breakdown of academic impact, for papers by Joshi J. Alumkal Breakdown of academic impact, for papers by Giorgio Massimini Breakdown of academic impact, for papers by Sofia Paul Breakdown of academic impact, for papers by Jean‐Marc Nabholtz Breakdown of academic impact, for papers by Simon Chowdhury Breakdown of academic impact, for papers by J Cuzick Breakdown of academic impact, for papers by Michael J. Demeure
Rankless by CCL
2026